NCT01363947 is a Phase 1 clinical trial of DNIB0600A in Non-Small Cell Lung Cancer, Ovarian Cancer, sponsored by Genentech, Inc..

Who is sponsoring NCT01363947?

NCT01363947 is sponsored by Genentech, Inc..

What drugs are being tested in NCT01363947?

Interventions in NCT01363947: DNIB0600A.

What condition does NCT01363947 study?

NCT01363947 studies Non-Small Cell Lung Cancer, Ovarian Cancer.

Is NCT01363947 still recruiting?

NCT01363947 is currently completed. Last updated 7 June 2017.

Last reviewed 2017-06-07 · How we verify

NCT01363947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Completed Phase 1 Last updated 7 June 2017

What this trial tests

Phase 1 trial testing DNIB0600A in Non-Small Cell Lung Cancer, Ovarian Cancer in 87 participants. Completed in 3 June 2016.

Timeline

14 June 2011

Primary endpoint
3 June 2016

3 June 2016

Quick facts

Lead sponsor	Genentech, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	87
Start date	14 June 2011
Primary completion	3 June 2016
Estimated completion	3 June 2016
Sites	7 locations across United States, Spain

Drugs / interventions tested

DNIB0600A — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer, Ovarian Cancer — all drugs for Non-Small Cell Lung Cancer, Ovarian Cancer →

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer, Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A administered as a single agent by intravenous (IV) infusion every three weeks (q3w) to participants with non-squamous NSCLC or non-mucinous, platinum-resistant ovarian cancer. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Drug resistance in ovarian cancer: from mechanism to clinical trial.
Wang L, Wang X, Zhu X, Zhong L, et al · · 2024 · cited 139× · PMID 38539161 · DOI 10.1186/s12943-024-01967-3
Exploration of the antibody-drug conjugate clinical landscape.
Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, et al · · 2023 · cited 90× · PMID 37639687 · DOI 10.1080/19420862.2023.2229101
Antibody-drug conjugates in lung cancer: dawn of a new era?
Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, et al · · 2023 · cited 89× · PMID 36631624 · DOI 10.1038/s41698-022-00338-9
Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
Li C, Zhang C, Li Z, Samineni D, et al · · 2020 · cited 44× · PMID 31852341 · DOI 10.1080/19420862.2019.1699768
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.
Newman DJ, Cragg GM. · · 2017 · cited 43× · PMID 28353637 · DOI 10.3390/md15040099
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X, Deng J, Zhang R, Xing J, et al · · 2023 · cited 15× · PMID 38162667 · DOI 10.3389/fimmu.2023.1335252
9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.
Reichert JM, Beck A, Lugovskoy AA, Wurch T, et al · · 2014 · cited 12× · PMID 24492298 · DOI 10.4161/mabs.27903
A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
Wang AJ, Gao Y, Shi YY, Dai MY, et al · · 2022 · cited 10× · PMID 36618922 · DOI 10.3389/fphar.2022.1093666

Verify or expand the search:

Other trials of DNIB0600A

Trials testing the same drug.

NCT01991210 — A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ov · Phase 2 · terminated
NCT01995188 — A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or N · Phase 1 · completed

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01363947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 7 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01363947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing